Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 11, 2011 - Issue 5
Submit an article Journal homepage
29
Views
6
CrossRef citations to date
0
Altmetric
Theme: Neurologic - Editorial

Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?

Enrico Franceschi Department of Medical Oncology, Bellaria-Maggiore Hospital, Azienda USL, Bologna, Italy
&
Alba A Brandes Department of Medical Oncology, Bellaria-Maggiore Hospital, Azienda USL, Bologna, Italy. [email protected]
Pages 657-660 | Published online: 10 Jan 2014

References

  • Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
  • Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol.28(7), 1168–1174 (2010).
  • Batchelor T, Mulholland P, Neyns B et al. The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a Phase III randomized study. Neuro-Oncology12(Suppl. 4), iv75 (2010).
  • Brandes AA, Tosoni A, Franceschi E et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a Phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother. Pharmacol.64(4), 769–775 (2009).
  • Chi AS, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist14(6), 621–636 (2009).
  • Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Presented at: World Federation of Neuro-Oncology Second Quadrennial Meeting. Edinburgh, Scotland, 4–7 May 2005 (Abstract 342).
  • Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer112(10), 2267–2273 (2008).
  • Cloughesy TF, Prados MD, Wen PY et al. A Phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J. Clin. Oncol. (Meeting Abstracts)26(15 Suppl.), 2010b (2008).
  • Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25(30), 4722–4729 (2007).
  • Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res, 13(4), 1253–1259 (2007).
  • Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol.27(5), 740–745 (2009).
  • Chen W, Delaloye S, Silverman DH et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol.25(30), 4714–4721 (2007).
  • Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol.28(11), 1963–1972 (2010).
  • Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol.8(7), 1277–1280 (1990).
  • Brandes AA, Franceschi E. New agents and new end points for recurrent gliomas. J. Clin. Oncol.29(9), e245–e246 (2011).
  • Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann. Oncol.21(12), 2324–2332 (2010).
  • Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J. Natl Cancer Inst.99(6), 428–432 (2007).
  • Committee for Medical Products for Human Use. Appendix 1 to the Guideline on the Evaluation of Anticancer Medicinal Products in Man. EMEA CPMP/EWP/205/95/Rev 3, London, UK (2008).
  • Federal Drug Administration. Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. US Department of Health and Human Services, MD, USA (2007).
  • Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat. Med.8(4), 431–440 (1989).
  • Ballman KV, Buckner JC, Brown PD et al. The relationship between six-month progression-free survival and 12-month overall survival end points for Phase II trials in patients with glioblastoma multiforme. Neuro. Oncol.9(1), 29–38 (2007).
  • Franceschi E, Brandes AA, Tosoni A et al. Can OS-6 replace PFS-6 as a primary endpoint in Phase II studies on glioblastoma patients given antiangiogenetic drugs? J. Clin. Oncol. (Meeting Abstracts)28(15 Suppl.), 2022 (2010).
  • Ocana A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J. Clin. Oncol.29(3), 254–256 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.